Skip to main content
PMC home page
Epidemiology and Infection logoLink to Epidemiology and Infection
. 1989 Dec;103(3):659–669. doi: 10.1017/s095026880003106x

The time course of the humoral immune response to rhinovirus infection.

W S Barclay 1, W al-Nakib 1, P G Higgins 1, D A Tyrrell 1
PMCID: PMC2249538  PMID: 2558033

Abstract

The specific humoral immune response of 17 volunteers to infection with human rhinovirus type 2 (HRV-2) has been measured both by neutralization and by ELISA. Six volunteers who had HRV-2-specific antibodies in either serum or nasal secretions before HRV-2 inoculation were resistant to infection and illness. Of the remaining 11 volunteers who had little pre-existing HRV-2-specific antibody, one was immune but 10 became infected and displayed increases in HRV-2-specific antibodies. These antibodies first increased 1-2 weeks after infection and reached a maximum at 5 weeks. All six resistant volunteers who had high pre-existing antibody and eight of the volunteers who became infected maintained their HRV-2-specific antibody for at least 1 year. At this time they were protected against reinfection. Two volunteers showed decreases in HRV-2-specific antibodies from either serum or nasal secretions. They became infected but not ill after HRV-2 inoculation 1 year later.

Full text

PDF
659

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acornley J. E., Chapple P. J., Stott E. J., Tyrrell D. A. Selection of variants of rhinoviruses. Arch Gesamte Virusforsch. 1968;23(3):284–287. doi: 10.1007/BF01241901. [DOI] [PubMed] [Google Scholar]
  2. BYNOE M. L., HOBSON D., HORNER J., KIPPS A., SCHILD G. C., TYRRELL D. A. Inoculation of human volunteers with a strain of virus isolated from a common cold. Lancet. 1961 Jun 3;1(7188):1194–1196. doi: 10.1016/s0140-6736(61)91941-9. [DOI] [PubMed] [Google Scholar]
  3. Barclay W. S., Al-Nakib W. An ELISA for the detection of rhinovirus specific antibody in serum and nasal secretion. J Virol Methods. 1987 Jan;15(1):53–64. doi: 10.1016/0166-0934(87)90048-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barclay W. S., Callow K. A., Sergeant M., al-Nakib W. Evaluation of an enzyme-linked immunosorbent assay that measures rhinovirus-specific antibodies in human sera and nasal secretions. J Med Virol. 1988 Aug;25(4):475–482. doi: 10.1002/jmv.1890250411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Buscho R. F., Perkins J. C., Knopf H. L., Kapikian A. Z., Chanock R. M. Further characterization of the local respiratory tract antibody response induced by intranasal instillation of inactivated rhinovirus 13 vaccine. J Immunol. 1972 Jan;108(1):169–177. [PubMed] [Google Scholar]
  6. CATE T. R., COUCH R. B., JOHNSON K. M. STUDIES WITH RHINOVIRUSES IN VOLUNTEERS: PRODUCTION OF ILLNESS, EFFECT OF NATURALLLY ACQUIRED ANTIBODY, AND DEMONSTRATION OF A PROTECTIVE EFFECT NOT ASSOCIATED WITH SERUM ANTIBODY. J Clin Invest. 1964 Jan;43:56–67. doi: 10.1172/JCI104894. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cate T. R., Rossen R. D., Douglas R. G., Jr, Butler W. T., Couch R. B. The role of nasal secretion and serum antibody in the rhinovirus common cold. Am J Epidemiol. 1966 Sep;84(2):352–363. doi: 10.1093/oxfordjournals.aje.a120648. [DOI] [PubMed] [Google Scholar]
  8. Couch R. B. The common cold: control? J Infect Dis. 1984 Aug;150(2):167–173. doi: 10.1093/infdis/150.2.167. [DOI] [PubMed] [Google Scholar]
  9. Fleet W. F., Couch R. B., Cate T. R., Knight V. Homologous and heterologous resistance to rhinovirus common cold. Am J Epidemiol. 1965 Sep;82(2):185–196. doi: 10.1093/oxfordjournals.aje.a120543. [DOI] [PubMed] [Google Scholar]
  10. HAMPARIN V. V., LEAGUS M. B., HILLEMAN M. R., STOKES J., Jr EPIDEMIOLOGIC INVESTIGATIONS OF RHINOVIRUS INFECTIONS. Proc Soc Exp Biol Med. 1964 Nov;117:469–476. doi: 10.3181/00379727-117-29611. [DOI] [PubMed] [Google Scholar]
  11. Hendley J. O., Gwaltney J. M., Jr, Jordan W. S., Jr Rhinovirus infections in an industrial population. IV. Infections within families of employees during two fall peaks of respiratory illness. Am J Epidemiol. 1969 Feb;89(2):184–196. doi: 10.1093/oxfordjournals.aje.a120928. [DOI] [PubMed] [Google Scholar]
  12. Hendley J. O. Rhinovirus colds: immunology and pathogenesis. Eur J Respir Dis Suppl. 1983;128(Pt 1):340–344. [PubMed] [Google Scholar]
  13. Holmes M. J., Reed S. E., Stott E. J., Tyrrell D. A. Studies of experimental rhinovirus type 2 infections in polar isolation and in England. J Hyg (Lond) 1976 Jun;76(3):379–393. doi: 10.1017/s0022172400055303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Perkins J. C., Tucker D. N., Knopf H. L., Wenzel R. P., Kapikian A. Z., Chanock R. M. Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness. Am J Epidemiol. 1969 Dec;90(6):519–526. doi: 10.1093/oxfordjournals.aje.a121098. [DOI] [PubMed] [Google Scholar]
  15. Scott E. J., Grist N. R., Eadie M. B. Rhinovirus infections in chronic bronchitis: isolation of eight possibly new rhinovirus serotypes. J Med Microbiol. 1968 Aug;1(1):109–117. doi: 10.1099/00222615-1-1-109. [DOI] [PubMed] [Google Scholar]
  16. Sherry B., Rueckert R. Evidence for at least two dominant neutralization antigens on human rhinovirus 14. J Virol. 1985 Jan;53(1):137–143. doi: 10.1128/jvi.53.1.137-143.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. TAYLOR-ROBINSON D. Studies on some viruses (rhinoviruses) isolated from common colds. Arch Gesamte Virusforsch. 1963;13:281–293. doi: 10.1007/BF01243854. [DOI] [PubMed] [Google Scholar]

Articles from Epidemiology and Infection are provided here courtesy of Cambridge University Press

RESOURCES